Cargando…

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients

Detalles Bibliográficos
Autores principales:	Dronca, Roxana, Liu, Xin, Lisa, Kottschade, Mcwilliams, Rob, Markovic, Svetomir, Dong, Haidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649372/ http://dx.doi.org/10.1186/2051-1426-3-S2-P298

Ejemplares similares

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
por: Vera Aguilera, Jesus, et al.
Publicado: (2020)

Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era
por: Youland, Ryan S., et al.
Publicado: (2017)

Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth
por: Liu, Xin, et al.
Publicado: (2013)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma
por: Youland, Ryan S., et al.
Publicado: (2017)

B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim
por: Gibbons, Rachel M., et al.
Publicado: (2012)

Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy
por: Davidson, Tara M, et al.
Publicado: (2022)

Neuropilin-1 cooperates with PD-1 in CD8(+) T cells predicting outcomes in melanoma patients treated with anti-PD1
por: Rossignol, Julien, et al.
Publicado: (2022)

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
por: Orme, Jacob J., et al.
Publicado: (2020)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

A Gender Factor in Shaping T-Cell Immunity to Melanoma
por: Dronca, Roxana S., et al.
Publicado: (2015)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

CD39(+)PD-1(+)CD8(+) T cells mediate metastatic dormancy in breast cancer
por: Tallón de Lara, Paulino, et al.
Publicado: (2021)

Functional differences between PD-1(+) and PD-1(-) CD4(+) effector T cells in healthy donors and patients with glioblastoma multiforme
por: Goods, Brittany A., et al.
Publicado: (2017)

Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma
por: van den Brom, Rob R. H., et al.
Publicado: (2018)

Therapy for metastatic melanoma: the past, present, and future
por: Finn, Laura, et al.
Publicado: (2012)

Circulating memory PD-1(+)CD8(+) T cells and PD-1(+)CD8(+)T/PD-1(+)CD4(+)T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
por: Liu, Jiang, et al.
Publicado: (2023)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis
por: Bartosińska, Joanna, et al.
Publicado: (2018)

Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
por: Ma, Ke, et al.
Publicado: (2020)

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
por: DeLeon, Thomas T., et al.
Publicado: (2020)

CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas
por: Niborski, Leticia Laura, et al.
Publicado: (2022)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Expansion of CD16-Negative Natural Killer Cells in the Peripheral Blood of Patients with Metastatic Melanoma
por: Holtan, Shernan G., et al.
Publicado: (2011)

Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
por: Camy, Florian, et al.
Publicado: (2020)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
por: Simon, Sylvain, et al.
Publicado: (2020)

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
por: Bochem, Jonas, et al.
Publicado: (2019)

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
por: Geng, Ruixuan, et al.
Publicado: (2023)

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
por: Smithy, James W., et al.
Publicado: (2017)

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
por: Babačić, Haris, et al.
Publicado: (2020)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells
por: Codarri Deak, Laura, et al.
Publicado: (2022)

Restored CD8(+)PD-1(+) T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma
por: Zhu, Qian, et al.
Publicado: (2022)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
por: Ascierto, Paolo A., et al.
Publicado: (2015)

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
por: Cao, Jinfeng, et al.
Publicado: (2017)

PD-L1 – PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection
por: Perry, Joseph A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mm9u5dcr88jiobkmbgtf56dsdn